Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a ...

Amgen, Inc. (“Amgen”) filed three petitions for inter partes review, challenging the validity of all claims in three patents ...

Current first-line treatment for advanced clear-cell renal cell carcinoma includes anti-PD1 or anti-PD-L1 immunotherapy in combination with a CTLA-4 inhibitor or a VEGF tyrosine kinase inhibitor ...

Additional Phase 2 data for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in ...

Researchers have discovered a strong association between the use of immune checkpoint inhibitors for cancer treatment and a ...

This hampers the effects of existing immunotherapies like CTLA-4 and PD-1 inhibitors, which work by mobilizing a person’s own immune system against their cancer. As a result, people with cold ...

Highlights Presentation Details: Abstract Title: Biomarker analysis from Phase 2 study of AgenT-797 (invariant natural killer T-cells), botensilimab (a Fc-enhanced CTLA-4 Inhibitor) with ...

Presentation Details: Abstract Title: Biomarker analysis from Phase 2 study of AgenT-797 (invariant natural killer T-cells), botensilimab (a Fc-enhanced CTLA-4 Inhibitor) with balstilimab (anti-PD ...

BAY43-9006 (Sorafenib) Small-molecule inhibitor BRAF, EGFR ... Immunological checkpoint blockade with anti-CTLA-4 and other monoclonal antibodies targeting costimulatory molecules is a promising ...